Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Global Glaucoma Therapeutics Market Poised for Growth; Set to Reach US$7.2 Billion by 2030 Glaucoma Therapeutics Market ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc.

It requires prompt treatment and can be vision-threatening. Neovascular glaucoma develops when new blood vessels form over your iris and the area where fluid usually drains from your eye.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma ...

Glenmark Pharmaceuticals Inc, USA on Wednesday said it has launched Travoprost ophthalmic solution used in the treatment of ...

“The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.”1 “ELIOS provides a tissue ...